A BW6 Specific CAR Designed To Protect Transplanted Tissue From Rejection
AssigneesThe Trustees of the University of Pennsylvania, One Lambda
InventorsJames L. Riley, Gavin Ellis, Jar-How Lee, Neng Jen Remi Shih, Thoa Nong
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for an HLA-BW6 specific chimeric antigen receptor (CAR). In certain embodiments the HLA-BW6 specific CAR is expressed on a T regulatory cell. In certain embodiments, the HLA-BW6 specific CAR protects transplanted tissue from rejection.
Claims86
A modified immune cell or precursor cell thereof, comprising a chimeric antigen receptor (CAR) having affinity for HLA-BW6, wherein the CAR comprises an HLA-BW6 binding domain, a transmembrane domain, and an intracellular domain.
A modified immune cell or precursor cell thereof, comprising a chimeric antigen receptor (CAR) having affinity for HLA-BW6, wherein the CAR comprises an HLA-BW6 binding domain, a CD8 hinge domain, a CD28 transmembrane domain, a CD28 costimulatory domain, and a CD3ζ intracellular domain.
A nucleic acid comprising a polynucleotide sequence encoding a chimeric antigen receptor (CAR) having affinity for HLA-BW6, wherein the CAR comprises an HLA-BW6 binding domain, a transmembrane domain, and an intracellular domain.
A method for achieving an immunosuppressive effect, in a subject in need thereof having an alloresponse or an autoimmune response, comprising administering to the subject a modified regulatory T cell comprising a chimeric antigen receptor (CAR) having affinity for HLA-BW6, wherein the CAR comprises an HLA-BW6 binding domain, a CD8 hinge domain, a CD28 transmembrane domain, a CD28 costimulatory domain, and a CD3ζ intracellular domain.
A method of treating diabetes in a subject in need thereof, comprising administering to the subject a modified regulatory T cell comprising a chimeric antigen receptor (CAR) having affinity for HLA-BW6, wherein the CAR comprises an HLA-BW6 binding domain, a CD8 hinge domain, a CD28 transmembrane domain, a CD28 costimulatory domain, and a CD3ζ intracellular domain.
An antibody or fragment thereof capable of binding HLA-BW6, wherein the antibody comprises at least one complementarity-determining region (CDR) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12.
A nucleic acid comprising a polynucleotide sequence encoding an antibody or fragment thereof capable of binding HLA-BW6, wherein the antibody comprises at least one complementarity-determining region (CDR) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.